Clinical Trials on Mild-to-moderate COVID-19 in Finland

Total 117 results

Finnish Institute for Health and Welfare
University of Helsinki; Tampere University; University of Eastern Finland; Strategic...

Recruiting

Adolescent Interpersonal Counseling in Primary Care

Major Depressive Disorder | Depressive Symptoms Mild to Moderate in Severity

Finland
Brown University

Completed

Dismantling Mindfulness: Contributions of Attention vs. Acceptance

Mild-moderate Unipolar Depression; Persistent Negative Affect

United States
University of Helsinki
Uppsala University; Göteborg University

Enrolling by invitation

Recovery After Critical Covid-19 Infection (RECOVID)

Covid-19

Finland
Helsinki University Central Hospital

Recruiting

AIR-program and HUS Internet Therapy Compared to Treatment as Usual in Functional Disorders and Post Covid-19 Condition

Functional Disorders | Post Covid-19

Finland
Helsinki University Central Hospital

Recruiting

Functional Ability, Symptoms and Quality of Life in Patients With Post Covid-19 Condition (LC-cohort)

Post Covid-19 Condition

Finland
Egalet Ltd

Completed

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Moderate-to-severe Chronic Noncancer Pain

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Australia, China
Royal Victoria Hospital, Canada

Not yet recruiting

Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder (STOPIT)

Moderate to Severe Opioid Use Disorder

Canada
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
Idera Pharmaceuticals, Inc.

Completed

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis | Actively Extending Plaque Psoriasis

United States
Butler Hospital
Brown University; The Miriam Hospital; Alzheimer's Association

Recruiting

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD (LINE-AD)

Mild Cognitive Impairment | Alzheimer Disease, Early Onset | Moderate Dementia

United States
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Chronic Plaque Psoriasis | Moderate to Severe Nail Psoriasis

United States, Australia
Jarmo Oksi

Completed

COVID-19: Salvage TOcilizumab as a Rescue Measure (COVIDSTORM)

Covid19

Finland
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

United States, United Kingdom, Belgium, Spain, France, Germany, Philippines, Brazil, Colombia, South Africa
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
University Hospital, Basel, Switzerland

Completed

Psychosocial Care During the COVID-19 Pandemic in Acute Hospitals

Covid-19 | COVID-19 Related Psychosocial Burden

Norway, Spain, Ireland, United Kingdom, Portugal, Poland, Austria, Belgium, Canada, Finland, France, Germany, Greece, Iran, Islamic Republic of, Italy, Switzerland
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

Moderate to Severe Palmoplantar Psoriasis

Belgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland
Helsinki University Central Hospital
Finnish Red Cross Blood Service

Active, not recruiting

Convalescent Plasma in the Treatment of Covid-19 (CP_COVID-19)

Covid19

Finland
Berlin Cures GmbH

Active, not recruiting

To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID (BLOC)

Long Covid

Germany, Austria, Finland, Spain, Switzerland
Clinical Urology and Epidemiology Working Group
Helsinki University Central Hospital; Oulu University Hospital; Kuopio University... and other collaborators

Recruiting

SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)

Covid19

Finland
Finnish Institute for Health and Welfare
Norwegian Institute of Public Health; Karolinska Institutet

Completed

Tobacco Use and COVID-19 Incidence in the Finnish General Population (Tobrisk-CoV)

Covid19 | SARS-CoV-2 Infection

Finland
UCB Biopharma SRL

Completed

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Canada
Finnish Institute for Health and Welfare
Norwegian Institute of Public Health; Karolinska Institutet

Active, not recruiting

Tobacco Use and Uptake of COVID-19 Vaccinations

Smoking | COVID-19 | Tobacco Use | Vaccination Refusal

Finland
Tampere University Hospital

Active, not recruiting

Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection

COVID-19 | SARS-CoV-2 Infection

Finland
Clinical Urology and Epidemiology Working Group
Helsinki University Central Hospital; Oulu University Hospital; Kuopio University... and other collaborators

Recruiting

SOLIDARITY Finland Plus Long-COVID

Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Acute Respiratory Disease

Finland
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
European Society for Emergency Medicine (EUSEM)...

Unknown

Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED (EUROCOV)

Covid19

Croatia, Finland, France, Greece, Italy
Theravance Biopharma

Completed

TD-0903 for ALI Associated With COVID-19

Acute Lung Injury (ALI) Associated With COVID-19 | Lung Inflammation Associated With COVID-19

Moldova, Republic of, United Kingdom, United States, Brazil, Finland, Romania, Ukraine
UKK Institute
University of Eastern Finland; North Karelia Hospital District

Unknown

eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19 (MySteps-CoV)

Type2 Diabetes

Finland
Bavarian Nordic

Completed

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

COVID-19 Disease

United States, Denmark, Belgium
Humanigen, Inc.

Completed

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids (KB003-04)

Moderate-to-Severe Asthma

France, United Kingdom, United States, Australia, Poland, Ukraine
CSL Behring

Completed

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019 (COVID-19)

United States
Tris Pharma, Inc.
Forest Laboratories

Completed

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

United States
Takeda
Zinfandel Pharmaceuticals Inc.

Terminated

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Germany, Switzerland, United Kingdom, Australia
aTyr Pharma, Inc.

Completed

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

SARS-CoV-2 (COVID-19) Severe Pneumonia

United States, Puerto Rico
Laurent Pharmaceuticals Inc.

Active, not recruiting

Study of LAU-7b for the Treatment of COVID-19 Disease in Adults (RESOLUTION)

COVID-19 Disease

United States, Canada
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden
Cytos Biotechnology AG

Terminated

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Moderate to Severe Allergic Asthma

United States, Czech Republic, Germany, Hungary, Israel, Poland, Russian Federation, Ukraine
Octapharma

Completed

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

Covid-19

United States, Russian Federation, Ukraine
Genentech, Inc.
Biomedical Advanced Research and Development Authority

Completed

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia (COVASTIL)

COVID-19 Pneumonia

United States, Spain, Brazil, Mexico
IDeA States Pediatric Clinical Trials Network
National Institutes of Health (NIH); University of Nebraska; University of Montana

Active, not recruiting

Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool (MoVeUP)

Telemedicine | Pediatric ALL | Vaccine Hesitancy | COVID-19 Vaccines

United States
Northwell Health

Completed

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

COVID | Sars-CoV2

United States
Restorbio Inc.

Terminated

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

COVID19

United States
BioNTech SE
Pfizer

Completed

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

SARS-CoV-2 Infection, COVID-19

United States, Spain, Finland, Poland, Mexico, Brazil
Takeda

Terminated

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Australia, United Kingdom, Switzerland
Hoffmann-La Roche
Gilead Sciences

Completed

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)

COVID-19 Pneumonia

United States, Spain, Brazil, Russian Federation
AstraZeneca

Completed

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

Chronic Obstructive Pulmonary Disease | COPD | Moderate to Very Severe COPD

United States, Canada
Eisai Inc.
Pfizer

Completed

The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility

Mild to Severe Alzheimer's Disease

United States
Women and Infants Hospital of Rhode Island
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

Baby2Home (B2H) Mobile Health Application

Post Partum Depression | Health Knowledge, Attitudes, Practice | COVID-19 Pandemic | Mental Health Wellness | Perinatal Depression

United States
Montefiore Medical Center
University of Bristol; The Fortune Society

Recruiting

Leveraging CHWs to Improve COVID-19 Testing and Mitigation Among CJIs Accessing a Corrections-focused CBO

Covid19

United States

Clinical Trials on Mild-to-moderate COVID-19 in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations